GLP-1 Medications (Weight-Loss Injections) and Sexual Desire: Understanding an Overlooked Effect

1️⃣ Interference with the Brain's Reward Pathways: The Dopamine–Serotonin Balance

GLP-1 medications affect not only the digestive system but also the central nervous system . Research shows that these medications alter dopamine and serotonin signaling pathways.

• Reduced sensitivity to rewards: GLP-1 medications may reduce the pleasure derived from food, nicotine, alcohol and other “sources of pleasure.” This may also indirectly weaken sexual desire , which uses the same reward pathways.
• Increased serotonin: Serotonin benefits mood, but high levels may have a suppressive effect on libido. This may explain reduced sexual desire in some patients.

2️⃣ Effects on Hormonal Balance

The biological basis of sexual desire depends on the balance between testosterone and estrogen . GLP-1 medications may affect this balance in two ways:

• Direct hormonal effects: In some men, testosterone levels may decrease, while in menopausal women, disruption of the estrogen/testosterone balance may lead to loss of libido.
• Indirect effects (improvement with weight loss): By reducing insulin resistance and inflammation, weight loss may improvehormone metabolism. This contributes to higher testosterone levels and increased sexual desire.

3️⃣ Psychological and Quality-of-Life Factors

Libido is not just about hormones; a person's self-confidence, body image and overall mood also play a determining role.

• Positive effects: Successful weight loss may increase self-confidence and satisfaction with one's body, strengthening sexual desire.
• Negative effects: Side effects observed in the first few months, such as fatigue, nausea and weakness , may temporarily reduce libido.

1) Comprehensive Patient Education and Expectation Management

• Proactive information: Before treatment, discussions should cover not only gastrointestinal side effects but also possible changes in libido and sexual function during treatment.
• Individual variability: The effects may be bidirectional (a decrease in some people, improvement in others). This spectrum should be clearly explained to the patient.
• Follow-up plan: During the first 8–12 weeks, ask about symptoms (energy, desire and side-effect profile) and, if needed, plan early adjustments to treatment.

2) Clinical Intervention and Adjustment Options

• Dosing strategy: When there is a marked loss of libido, dose reduction or slower titration improves tolerability in most patients.
• Side-effect management: Active management of nausea, fatigue and appetite changes (nutritional advice, an antiemetic plan and hydration) may increase energy levels and indirectly improve sexual desire.
• Drug–drug interactions: Concomitant antidepressants (particularly serotonergic agents), antipsychotics or beta-blockers may affect libido; treatment should be reviewed holistically.
• Timing and lifestyle: Exercise, sleep hygiene and stress management may be recommended, along with scheduling sexual activity for times when side effects are least noticeable during the day.

3) Hormonal Assessment and Consultation When Necessary

• In male patients: If symptoms are present, assessment of free testosterone, total testosterone and SHBG levels should be considered, with an endocrinology consultation when necessary.
• Menopause/Perimenopause: Symptoms such as hot flashes, sleep disturbances and mood fluctuations have a marked effect on libido; a holistic approach should be planned.
• Obesity and weight loss: The hormonally beneficial effect of fat loss may increase libido over time; declines early in treatment are often temporary.

💬 A Message for Patients

If you notice a change in sexual desire while using GLP-1, do not hesitate to mention it. This is usually temporary and can be easily managed with your doctor through small adjustments in dose or timing. These changes do not need to make you feel guilty or anxious — a biological effect of the medications on the brain is involved.

🩺 Clinical Takeaway for Doctors

GLP-1 RAs are first-line options because of their benefits in treating diabetes and obesity. Changes in libido are not a reason to discontinue treatment, but a quality-of-life aspectthat needs to be managed. Therefore:

• Maintain open communication with the patient; asking about symptoms increases trust in clinical care.
• Dose optimization and hormonal assessment improve symptoms in most cases.
• Psychological support or lifestyle improvements contribute to the overall success of treatment.